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Abstract
Background: Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia
interventions are at high risk of a second relapse. We studied the impact of minimal residual disease (MRD)- and
graft-vs.-host disease (GvHD)-guided multiple consolidation chemotherapy and donor lymphocyte infusions (DLIs)
to prevent second relapse in patients with acute leukemia relapsing post-transplant and who achieved complete
remission after induction chemotherapy and DLI.
Methods: Forty-seven subjects with acute leukemia relapsing after an allotransplant and who achieved complete
remission after post-relapse induction chemotherapy and DLI were eligible. The use of consolidation chemotherapy
and DLI was guided by the results of MRD testing and whether or not DLI caused acute and/or chronic GvHD.
Outcomes were compared with those of 34 similar historical controls who did not receive consolidation chemotherapy
and DLIs after induction chemotherapy and DLI.
Results: One-year cumulative incidence of relapse (CIR; 22 % 95 % confidence interval (10, 35 %) vs. 56 % (39, 73 %);
P < 0.0001), leukemia-free survival (LFS; 71 % (57, 84 %) vs. 35 % (19, 51 %); P < 0.0001), and survival (78 % (66, 90 %)
vs. 44 % (27, 61 %); P < 0.0001) was significantly better in subjects than controls. In multivariate analyses, no chronic
GvHD after therapy (hazard ratio (HR) = 3.56 (1.09, 11.58); P = 0.035) and a positive MRD test after therapy (HR = 21.04
(4.44, 94.87); P < 0.0001) were associated with an increased CIR.
Conclusion: These data suggest MRD- and GvHD-guided multiple consolidation chemotherapy and DLIs reduce CIR
and increase LFS and survival compared with controls in persons relapsing after allotransplant for acute leukemia.
Trial registration: ChiCTR-ONC-12002912. Donor lymphocyte infusion for the treatment of leukemia relapse following
allogeneic hematopoeitic stem cell transplant.
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Background
Leukemia relapse is still a major problem after allo-
transplants for acute leukemia [1, 2]. Therapy of post-
transplant relapse includes stopping immune suppres-
sion and giving anti-leukemia chemotherapy and donor
lymphocyte infusions (DLIs). Schmid et al. reported a
34 % complete remission rate from chemotherapy and
DLI in 171 persons relapsing after an allotransplant for
acute leukemia with a 2-year survival of 21 ± 3 % SD
[3]. We recently reported a 64 % (95 % confidence
interval (CI), 50–76 %) complete remission rate and
36 % (23, 49 %) 1-year leukemia-free survival (LFS)
and 20 % (9, 33 %) 2-year LFS in 50 persons relapsing
after an allotransplant [4]. Clearly, these results need
improvement.
In persons receiving an allotransplant for acute
leukemia, we reported an association between a positive
minimal residual disease (MRD)-test after transplant
and an increased risk of subsequent relapse [5–8]. Fur-
thermore, in persons relapsing after an allotransplant
and who achieve complete remission after induction
chemotherapy and DLIs, the association between a posi-
tive MRD test and an increased risk of a second relapse
was also reported in our previous study [4]. Also, per-
sons developing chronic GvHD after receiving DLI for
leukemia relapse after a first allotransplant have a lower
likelihood of a second relapse compared with similar
persons not developing chronic GvHD [4]. And, Mo
et al. [9] also reported persons with chronic GvHD after
DLI was associated with a greater frequency of a nega-
tive MRD test and lower likelihood of subsequent re-
lapse compared with similar persons not developing
chronic GvHD. Based on these data, we designed a study
to determine whether giving additional consolidation
chemotherapy and DLI might decrease likelihood of
second relapse in persons without chronic GvHD or with
a positive MRD test after initial post-relapse therapy with
induction chemotherapy and DLI.
Methods
Eligibility
From January 1, 2013, to February 28, 2015, subjects
receiving non-T cell-depleted an allotransplant at
Peking University Institute of Hematology were eligible
if they met the following criteria: (1) acute leukemia
without t(9;22); (2) relapse after an allotransplant; (3)
had full or partial-donor chimerism; and (4) received
re-induction chemotherapy and DLI and achieved a
complete remission. The study was approved by the
Ethics Committee of Peking University People’s Hos-
pital, and written informed consent was obtained from
all subjects in accordance with the Declaration of




From January 1, 2013, to February 28, 2015, 87 consecu-
tive subjects ages 4–58 years relapsing after an allotrans-
plant were screened for eligibility. Eight received only
supportive care and nine received chemotherapy but not
DLI because no donor was available (N = 6) or because
there were no residual donor cells at time of relapse
(N = 3). Forty-seven (67 % (56, 77 %)) of the remaining
70 subjects receiving re-induction chemotherapy and
DLI to control relapse post-transplant achieved a
complete remission and were eligible for this study.
Controls were selected from among 69 similar subjects
relapsing after allotransplant at our center from January
1, 2000, to December 31, 2008. We excluded five receiv-
ing only supportive care, seven who did not receive DLI
because no donor was available (N = 4) or because there
were no residual donor cells at time of relapse (N = 3),
and three who received a second allotransplant. In the
remaining 54 subjects receiving re-induction chemo-
therapy and DLI, 34 (63 % (50, 75 %)) subjects achieved
a complete remission and served as controls.
Therapy-protocol
Post-transplant immune suppression was discontinued
immediately upon relapse. All subjects then received
induction chemotherapy (see below). DLI was given
48–72 h after completing chemotherapy (see below).
Subjects not achieving a complete remission after a second
course of induction chemotherapy and DLI were excluded.
Subjects achieving a complete remission had MRD testing
at 1, 2, 3, 6, 9, and 12 months and at 6-month intervals
thereafter. Consolidation chemotherapy and additional
DLIs (see below) were given based on the results of MRD
testing and whether the subjects developed GvHD. Sub-
jects with a positive MRD test received consolidation
chemotherapy and DLIs monthly until the MRD test
became negative. If white blood cells (WBC) counts
recovered within 30 days, consolidation chemotherapy
and DLIs were given monthly until MRD test became
negative; if WBC counts recovered after 30 days, consoli-
dation chemotherapy and DLIs were given when WBC
counts recovered post-chemotherapy. Subjects with a
negative MRD test and no GvHD received consolidation
chemotherapy and DLIs at 3, 6, and 9 months. If MRD
test was persistently negative and GvHD never resolved,
consolidation chemotherapy and DLI was not given. If the
MRD test was persistently negative but GvHD resolved,
consolidation chemotherapy and DLI were given at
6 months. If the MRD test was positive again and GvHD
resolved, consolidation chemotherapy and DLI were given
monthly until the MRD test became negative again. If
MRD test was positive again but GvHD never resolved,
consolidation chemotherapy without DLI was given
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monthly until the MRD test became negative again. Inter-
ventions were continued until 1 year after achieving
complete remission (Fig. 1a).
Induction chemotherapy in persons with acute myeloid
leukemia (AML) was homoharringtonine, 2 mg/mE + 2/
day for 5 days, aclacinomycin, 10 mg/mE + 2/day for
5 days and cytarabine, 100 mg/mE + 2/day for 5 days
(HAA). Induction chemotherapy in persons with acute
lymphoblastic leukemia (ALL) was cyclophosphamide,
800 mg/mE + 2/day for 2 days, vincristine 1 mg/mE + 2/
day on day 1, daunorubicin, 40 mg/mE + 2/day for 3 days,
and prednisone, 60 mg/day for 7 days (CODP). Subjects
not achieving a complete remission after the first course
of induction chemotherapy and DLI received a second
course of induction chemotherapy with HAA or fludara-
bine, 30 mg/mE + 2/day for 5 days, cytarabine, 1 g every
12 h for 10 doses and granulocyte-colony stimulating fac-
tor (G-CSF), 300 μg/day for 6 days (FLAG) in subjects
with AML and CODP or methotrexate (MTX), 1 g/mE +
2/day for 1 days and pegaspargase, 2000 U/mE + 2/day
for 1 day in subjects with ALL. Consolidation chemother-
apy in persons with AML was AA or HAA. Consolidation
chemotherapy in persons with ALL was CODP or MTX,
1 g/mE + 2/day for 1 day.
DLIs used G-CSF mobilized blood cells followed by
cyclosporine (CSA) or MTX to prevent GvHD. Details are
reported [10, 11]. Median dose of mononuclear cells
(MNC) for each infusion was 1.0 × 10E + 8/kg. Subjects
could receive up to four courses of DLIs. Subjects receiving
DLIs from a human leucocyte antigen (HLA)-haplotype-
matched donor or an HLA-matched unrelated donor re-
ceived CSA for 6 weeks after each infusion to prevent
GvHD [10]. Subjects receiving DLIs from a HLA-identical
related donor received CSA or MTX for 2–4 weeks after
each infusion to prevent GvHD [11]. In subjects receiving
DLI from a HLA-identical related donor with prior ≥grade
2 acute GvHD or ≥moderate chronic GvHD received CSA
after DLI whereas others received MTX. The starting dose
of CSA was 2.5 mg/kg/day and the dose was adjusted to
maintain a plasma concentration 150–250 ng/ml. MTX,
10 mg, was given on days +1, +4, +8, +15, and +21.
MRD testing
We used to two strategies to test for MRD in bone marrow
samples: (1) aberrant leukemia-associated immune pheno-
types (LAIPs) detected by four-color flow cytometry (FCM)
and (2) WT1 messenger RNA (mRNA) levels detected by
polymerase chain reaction (PCR) [5–8, 12]. LAIPs were de-
tected by four-color FCM. Different antibody combinations
were used in B-ALL, T-ALL, and AML as described [5, 12].
7.5 × 10E + 5 − 1 × 10E + 6 events were routinely analyzed.
FCM-positive was defined as >0.01 % of cells with a LAIPs
phenotype in ≥1 bone marrow samples. Sensitivity was
79 % and specificity was 85 % for persons with ALL [5].
WT1 mRNA level was evaluated by TaqMan-based RQ-
PCR technology as described [6]. WT1-positive was defined
as a transcript level >0.60 % in ≥1 bone marrow samples.
Sensitivity was 69 % and specificity was 91 % for persons
Fig. 1 The diagram of intervention strategy. a The diagram of intervention strategy. b The diagram of patient subgroups
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with AML [7]. Subjects with a positive LAIP or WT1 test
were declared MRD test positive [7, 8].
Chimerism analysis
Chimerism analysis was performed by using DNA finger-
printing of short tandem repeats (STRs) from whole cell
population in peripheral blood samples. If patients
received transplant from sex-mismatched donors, chi-
merism analysis was also performed by using fluores-
cent in situ hybridization (FISH) for sex chromosomes
in the bone marrow samples. Evaluations of chimerism
were performed at the time of relapse post-transplant
and at 1, 2, 3, 6, 9, and 12 months after induction
chemotherapy and at 6-month intervals thereafter.
Transplants
Details of transplants including conditioning regimen,
graft composition, GvHD prophylaxis, and supportive care
are described [13–15]. Recipients of HLA-identical related
transplants received cyclophosphamide, 1.8 g/mE + 2/day,
for 2 days and 1 dose of 7.7 Gy total body radiation at
3.2 cGy/min or busulfan, 3.2 mg/kg/day IV for 3 days,
and cyclophosphamide. Recipients of HLA-haplotype-
matched related transplants and of HLA-matched unre-
lated transplants also received anti-human thymocyte
immunoglobulin (ATG), 2.5 mg/Kg/d IV days −5 to −2
(Genzyme Corp, Boston, MA, USA). Grafts consisted of
G-CSF mobilized bone marrow cells and peripheral
blood cells. CSA, mycophenolate mofetil, and short-
term MTX were given to prevent or modify GvHD.
Definitions
Given that thrombocytic recovery could be postponed
by factors other than leukemia and cytotoxic therapy
(i.e., GvHD, virus, drugs), complete remission was defined
as less than 5 % bone marrow blasts without evidence of
dysplasia in bone marrow, no myeloblasts with Auer rods,
no extra-medullary leukemia, and ANC ≥ 1 × 10E + 9/L.
Leukemia relapse was defined as recurrence of ≥5 % bone
marrow blasts or of ≥1 extra-medullary sites of leukemia.
Neutrophil recovery was defined as an absolute neutrophil
count (ANC) ≥ 0.5 × 10E + 9/L, and the time of neutrophil
recovery was defined as the interval from the end of
chemotherapy to the date of neutrophil recovery. Platelet
recovery was defined as a platelet count ≥ 20 × 10E + 9/L
for 7 consecutive days without transfusions, and the time
of platelet recovery was defined as the interval from the
end of chemotherapy to the date of platelet recovery. Sur-
vival was defined as interval from complete remission
after post-relapse induction chemotherapy to death from
any cause. LFS was defined as interval from the same start
point to leukemia relapse or death whichever occurred
first. Grading of acute GvHD and chronic GvHD used
published criteria [16, 17].
Statistics
The study was powered to detect 60 % LFS based on a
reference rate of 35 % at 1 year derived using data from
our center (unpublished). The primary end point was
1-year LFS. Secondary endpoints included incidence of
acute and chronic GvHD, 1-year cumulative incidence
of relapse (CIR), and survival.
CIRs, transplant-related mortality (TRM), and GvHD
were calculated using a competing risk model. LFS and
survival were calculated using the Kaplan-Meier method
and compared using the log-rank test. Univariate ana-
lyses were performed using the χ2 test for categorical
variables and the Mann-Whitney test for continuous
variables. Multivariate analyses were performed using a
Cox proportional hazards model. Potential interactions
were tested, screened, and extracted from the analysis.
Endpoint of follow-up for surviving subjects was February
28, 2016. Unless specified, all P values were two-sided and
a P value <0.05 was considered significant. SPSS and R
software packages were used for data analyses.
Results
Subject variables
Subject-related variables of trial subjects and controls are
displayed in Table 1. Although most were similar, trial
subjects were more likely to receive a HLA-haplotype-
matched transplant (66 % (52, 78 %) vs. 56 % (39, 71 %);
P = 0.037; Table 1). Besides, in 47 trial subjects achieving
complete remission, platelet did not achieve 100 × 10E +
9/L at the time of complete remission in 7 subjects, and
in 34 controls achieving complete remission, platelet did
not achieve 100 × 10E + 9/L in 6 controls.
Twenty-six trial subjects (55 % (41, 69 %)) were MRD
test negative when they achieved a complete remission.
Twelve others became MRD test negative after the first
course of consolidation chemotherapy and DLI. Two
more subjects became MRD test negative after the
second course of consolidation chemotherapy and DLI,
and one subject became MRD test negative after a third
course of consolidation chemotherapy and DLI. Four-
teen of the 26 subjects (54 % (35, 71 %)) with a negative
MRD test when they achieved remission had ≥1 subse-
quent positive MRD tests. All received consolidation
chemotherapy and DLIs, and 11 became MRD test nega-
tive. Finally, 38 trial subjects (81 % (67, 90 %)) were con-
tinuously MRD test negative (Fig 1b). Twenty-one trial
subjects received one course of consolidation chemo-
therapy and DLI, 18 received two courses of consolida-
tion chemotherapy and DLI, 7 received three courses of
consolidation chemotherapy and DLI, and 1 received four
courses of consolidation chemotherapy and DLI (Table 1).
All trial subjects achieved neutrophil recovery with a
median time of 17 days (range, 10–30 days). Forty-five
trial subjects achieved platelet recovery with a median
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Table 1 Characteristics of patients in study group and historical group (n = 81)
Characteristics Study group Historical group P
Patients’ number 47 34
Age (years, range) 28 (4-58) 25 (7-57) 0.696
Gender 0.294
Male (%) 29 (62) 17 (50)
Female (%) 18 (38) 17 (50)
Diagnosis (%) 0.300
Acute myeloid leukemia 25 (53) 22 (65)
Acute lymphoid leukemia 22 (47) 12 (35)
Remission state pre-HSCT (%) 0.154
CR1 39 (83) 25 (73)
CR2 5 (11) 9 (27)
CR3 2 (4) 0 (0)
NR 1 (2) 0 (0)
Cytogenetic subgroupsa (%) 0.285
Intermediate 30 (64) 18 (53)
Poor 10 (21) 6 (18)
Not available 7 (15) 10 (29)
Numbers of induction chemotherapies (%) 0.214
≤2 39 (85) 25 (74)
>2 7 (15) 9 (26)
Donor types (%) 0.037
HLA-identical related 11 (23) 15 (44)
Haploidentical related 31 (66) 19 (56)
Unrelated 5 (11) 0 (0)
HLA-mismatch (%) 0.230
0 locus mismatch 4 (11) 0 (0)
1 locus mismatch 3 (8) 4 (21)
2 locus mismatch 10 (28) 7 (37)
3 locus mismatch 19 (53) 8 (38)
Donor-patient sex match (%) 0.377
Female-female 3 (6) 6 (18)
Female-male 13 (28) 7 (21)
Male-male 18 (38) 14 (41)
Male-female 13 (28) 7 (21)
ABO match (%) 0.994
Match 31 (66) 22 (65)
Major mismatch 6 (13) 5 (15)
Minor mismatch 6 (13) 4 (12)
Major and minor mismatch 4 (9) 3 (9)
Conditioning regimen (%) 0.635
TBI-based 3 (6) 1 (3)
Bu-based 44 (94) 33 (97)
Acute GvHD of grades 2–4 pre-DLI 14 (30) 9 (27) 0.744
Acute GvHD of grades 3–4 pre-DLI (%) 4 (9) 0 (0) 0.135
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time of 20 days (range, 8–56 days). Besides, before disease
relapse, 8 trial subjects received chemotherapy and DLI
due to a positive MRD test.
Relapse
Nine subjects had persistent MRD-positive tests includ-
ing six after multiple courses of consolidation chemo-
therapy and DLI and three who were transiently MRD
test negative. Seven relapsed and two other died of TRM.
This contrasts with relapse in only 7 of 38 subjects who
were consistently MRD test negative (P = 0.001). CIR was
22 % (10, 35 %) at 1 year and 35 % (19, 52 %) at 2 years
(Table 2 and Fig. 2). In multivariate analyses, no chronic
GvHD after DLI (HR = 3.56 (1.09, 11.58); P = 0.035) and
persistent positive MRD tests after DLI (HR = 21.04 (4.66,
94.87); P < 0.0001; Table 3) were associated with increased
relapse risks.
GvHD
Nine trial subjects developed acute GvHD after DLI. Of
the nine subjects, one developed grade 1 acute GvHD,
five developed grade 2 acute GvHD, two developed
grade 3 acute GvHD, and one developed grade 4 acute
GvHD. Skin affected occurred in eight subjects, liver
affected occurred in two, and intestinal tract affected oc-
curred in four. Cumulative incidences of ≥grade 2 acute
GvHD and ≥grade 3 acute GvHD were 25 % (15, 39 %) and
11 % (3, 22 %) (Table 2). Besides, 37 subjects developed
chronic GvHD, 31 subjects developed ≥moderate chronic
GvHD. Of the 37 subjects, 5 had a history of acute
GvHD after DLI. Cumulative incidence of chronic GvHD
and ≥moderate chronic GvHD at 1 year were 52 % (39,
65 %) and 49 % (34, 64 %) (Table 2). Cumulative
Table 1 Characteristics of patients in study group and historical group (n = 81) (Continued)
Chronic GvHD pre-DLI (%) 10 (21) 12 (35) 0.162
Moderate or severe chronic GvHD pre-DLI (%) 4 (9) 6 (18) 0.307
Interval from HSCT to relapse (day) (range) 204 (39-2180) 241 (40-2405) 0.737
BM blasts at the time of relapse (%) (range) 29 (7-93) 28 (9-92) 0.513
Chimerism at the time of relapse (%) 0.294
Full-donor chimerism 34 (72) 28 (82)
Partial-donor chimerism 13 (28) 6 (18)
Times of DLI after induction chemotherapy plus DLI NA
1 21 (45) 0 (0)
2 18 (38) 0 (0)
3 7 (15) 0 (0)
4 1 (2) 0 (0)
MNCs in DLI (×108/kg, range) 1.00 (1.00-1.50) 1.00 (0.70-1.70) 0.957
CD3+ cells in DLI (×108/kg, range) 0.34 (0.15-0.64), 0.37 (0.15-0.74), 0.653
CD4+ cells in DLI (×108/kg, range) 0.20 (0.10-0.42) 0.23 (0.09-0.31) 0.732
CD8+ cells in DLI (×108/kg, range) 0.12 (0.06-0.28) 0.14 (0.05-0.31) 0.657
CD14+ cells in DLI (×108/kg, range) 0.26 (0.04-0.48) 0.29 (0.09-0.61) 0.432
CD34+ cells in DLI (×106/kg, range) 0.48 (0.14-1.44) 0.54 (0.12-1.58) 0.354
HSCT hematopoietic stem cell transplantation, CR1 first complete remission, CR2 second complete remission, CR3 third complete remission, NR non-remission, HLA
human leucocyte antigen, TBI total body irradiation, Bu busulfan, GvHD graft-vs.-host disease, DLI donor lymphocyte infusion, BM bone marrow, NA not available,
MNC mononuclear cell
aThe cytogenetic subgroups are according to the published data [35, 36]
Table 2 Outcomes of patients in study group and historical






Patients’ number 47 34
Cumulative incidence of relapse at 1 year (%) 22 56 <0.0001
Acute GvHD of grades 2–4 (%) 25 35 0.149
Acute GvHD of grade 3–4 (%) 11 15 0.366
Chronic GvHD (%) 52 33 0.039
Moderate or severe chronic GvHD (%) 49 23 0.005
TRM at 1 year (%) 9 6 0.064
LFS at 1 year (%) 71 35 <0.0001
Survival at 1 year (%) 78 44 <0.0001
Causes of mortality (n) 11 30
Relapse (n) 7 25
Infection (n) 3 3
TMA (n) 1 0
GvHD (n) 0 2
GvHD graft-vs.-host disease, TRM treatment-related mortality, LFS leukemia-free
survival, TMA thrombotic microangiopathy
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incidences of chronic and ≥moderate chronic GvHD in-
creased gradually with increased numbers of courses of
consolidation chemotherapy and DLI: chronic GvHD: 1
course 35 % (18, 52 %) vs. 2 courses 72 % (57, 86 %) vs.
3–4 courses 100 % (83, 100 %); P = 0.002) and ≥moderate
chronic GvHD: 1 course 30 % (19, 41 %) vs. 2 courses
70 % (55, 85 %) vs. 3–4 courses 100 % (92, 100 %); P =
0.003). In contrast, cumulative incidences of ≥grade 2
acute GvHD and ≥grade 3 acute GvHD were not signifi-
cantly associated with numbers of courses of consolida-
tion chemotherapy and DLI (P = 0.17 and P = 0.77).
LFS and survival
Eleven trial subjects died, seven died of relapse, three died
of infection, and one died of thrombotic microangiopathy.
Median LFS was 23 months (range, 4–38 months). LFSs
at 1 and 2 years were 71 % (59, 85 %) and 53 % (37, 69 %).
Median survival was 32 months (range, 8–38 months).
Survivals at 1 and 2 years were 78 % (66, 90 %) and 72 %
(59, 86 %; Table 2 and Fig. 2).
Comparison of study subjects and controls
Study subjects had a higher rate of persistent MRD-
negative tests than controls (81 % (67, 90 %) vs. 9 %
(3, 23 %); P < 0.0001). CIR in the study cohort was less
than in controls (22 % (10, 35 %) vs. 56 % (39, 73 %);
P < 0.0001). Cumulative incidences of ≥grade 2 and ≥grade
3 acute GvHD were similar to controls (P = 0.149 and
P = 0.366). One-year cumulative incidences of chronic
GvHD (52 % (39, 65 %) vs. 33 % (12, 54 %); P = 0.039)
and ≥moderate chronic GvHD (49 % (34, 64 %) vs.
23 % (8, 38 %); P = 0.005) was significantly higher in
subjects vs. control. One-year LFS was significantly bet-
ter in subjects vs. controls (71 % (57, 84 %) vs. 35 %
(19, 51 %), P < 0.0001). One-year survival was also bet-
ter (78 % (66, 90 %) vs. 44 % (27, 61 %); P < 0.0001;
Table 2 and Fig. 2).
Discussion
We found MRD test results and GvHD-guided multiple
consolidation chemotherapy and DLIs reduced CIR and
improved LFS and survival compared with historical
controls in patients with relapsed acute leukemia after
allo-hematopoietic stem cell transplantation (HSCT).
This was probably due to that the use of multiple
consolidation chemotherapy and DLIs after induction
chemotherapy and DLI could make more patients
achieve and maintain a persistent negative MRD test.
Although induction chemotherapy and DLI could make
patients achieve complete remission in patients with
relapsed acute leukemia after transplant, only 55 % of
patients achieved a negative MRD test, and 54 % of these
patients had subsequent positive MRD tests. But, after
multiple consolidation chemotherapy and DLIs, 81 % of
patients finally maintained a negative MRD test, com-
pared with a 9 % of negative MRD test rate in historical
control (P < 0.0001). Many studies already report a posi-
tive MRD test is associated with an increased relapse
risk post-transplant [5–7, 12, 18, 19]. As well, based on
the results of MRD tests, preemptive use of DLI could
make patients achieve a negative MRD test and prevent
relapse post-transplant in patients with standard risk
acute leukemia [8]. Besides, multiple consolidation
chemotherapy and DLIs also induced chronic GvHD
and stronger graft-vs.-leukemia (GvL) effects. Our
present study suggested that the incidence of chronic
GvHD in study group was significantly higher than that
in historical control (52 vs. 33 %, P = 0.039), as well as,
the incidence of chronic GvHD post-DLI increased grad-
ually with increased numbers of courses of consolidation
chemotherapy and DLI (P = 0.002). Many researchers
have already demonstrated that the development of
chronic GvHD post-DLI was a favorable factor of CIR
and survival in patients with relapsed acute leukemia
after allo-HSCT [3, 4, 20, 21]. Therefore, all of these data
Fig. 2 Comparison of outcomes after complete remission between study group and historical group. a Cumulative incidence of re-relapse after
complete remission. b Leukemia-free survival (LFS) after complete remission. c Survival after complete remission. From January 1, 2013, to February 28,
2015, consecutive 47 patients received multiple consolidation chemotherapy and DLI and were finally included in study group. From January 1, 2000,
to December 31, 2008, 34 patients only received induction chemotherapy plus DLI and were finally defined as historical group
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suggested that the application of multiple consolidation
chemotherapy and DLIs after induction chemotherapy
and DLI could prevent the second relapse in patients
with relapsed acute leukemia post-transplant, by inducing
chronic GvHD and maintaining the negative MRD test.
Severe GvHD is a major risk of multiple consolidation
chemotherapy and DLIs, which is usually correlated with
higher TRM. However, we found that the incidences
of ≥grade 2 acute GvHD and ≥grade 3 acute GvHD in
study group were all similar to that in historical control
(P = 0.149 and P = 0.366). And ultimately, there was no
significant difference in the incidence of TRM between
two groups (8.8 vs. 6.4 %, P = 0.064). A probable reason is
due to the application of immunosuppressive agents for
2–4 weeks in patients receiving DLI from HLA-identical
related donors and for 6 weeks in patients receiving DLI
from haploidentical related donors or unrelated donors.
Our previous study suggested that the duration of im-
munosuppressive agents used after DLI was the only risk
factor for the development of ≥grade 3 acute GvHD after
DLI (P = 0.018) and the cumulative incidence of ≥grade-3
acute GvHD in patients receiving immunosuppressive
agents for ≥6 weeks was only 9.3 % [22]. Besides, the ap-
plication of immunosuppressive agents for ≥6 weeks after
DLI from haploidentical related donors and 2–4 weeks
after DLI from HLA-identical related donors could pre-
serve GvL effects at the same time could reduce the inci-
dence of ≥grade 3 acute GvHD after DLI [10, 11]. As
well, our present study also suggested that cumulative in-
cidence of ≥grade 2 acute GvHD and ≥grade 3 acute
GvHD were not significantly associated with numbers of
courses of consolidation chemotherapy and DLI (P = 0.17
and P = 0.77), although cumulative incidences of chronic
GvHD and ≥moderate chronic GvHD increased gradually
with increased numbers of courses of consolidation
chemotherapy and DLI (P = 0.003). Another probable
reason is due to the use of G-CSF mobilized peripheral
blood cells instead of unstimulated lymphocytes. Huang
et al. [23, 24] reported that the application of G-CSF
may modulate the polarization of T cells from a Th1 to a
Th2 phenotype and indirectly induce T-cell hypo-
responsiveness through the selective increase of DC2
cells and monocytes and the down-regulation of the
CD28/B7 co-stimulatory signal. Moreover, Morris et al.
[25] confirmed that using G-CSF during blood cell
mobilization augments NK-T-cell-dependent CD8+ cyto-
toxicity and purportedly separates GvHD and GvL. Our
previous study also suggested that compared with
chemotherapy and DLI with unstimulated lymphocytes,
chemotherapy and G-CSF mobilized peripheral blood
cells infusion tended to be associated with a higher
complete remission rate (7/9 vs. 3/5) and lower inci-
dence of ≥grade 3 acute GvHD (0/9 vs. 1/5) in patients
with relapsed hematological malignancies after HLA-
identical related HSCT [26]. Therefore, although trial
subjects received multiple consolidation chemotherapy
and DLIs, no subjects died of GvHD. Another risk of
multiple consolidation chemotherapy and DLIs is pan-
cytopenia, which usually leads to higher infection-related
mortality. Raiola AM et al. [21] found that chemotherapy
and DLI with unstimulated lymphocytes was typically as-
sociated with a higher incidence of pancytopenia (18/
100) and a longer duration of pancytopenia (median
duration, 90 days). However, chemotherapy and G-CSF
mobilized peripheral blood cells infusion was associ-
ated with a lower incidence of pancytopenia (2/57)
[27]. In this study, all trial subjects achieved neutrophil







Remission status pre-HSCT 0.748
Cytogenetic subgroupsa 0.294
Numbers of induction chemotherapies 0.654
Donor types 0.735
HLA-mismatch 0.090
Donor-patient sex match 0.932
ABO match 0.154
Conditioning regimen 1.000
Acute GvHD of grades 2–4 pre-DLI 0.726
Chronic GvHD pre-DLI 0.703
Interval from HSCT to relapse 0.695
BM blasts at the time of relapse 0.443
Chimerism at the time of relapse 0.467
MNCs in DLI 0.388
CD3+ cells in DLI 0.252
CD4+ cells in DLI 0.242
CD8+ cells in DLI 0.348
CD14+ cells in DLI 0.209
CD34+ cells in DLI 0.817
Acute GvHD of grades 2–4 post-DLI 0.413
Chronic GvHD post-DLI 0.002
Persistent MRD-positive state post-DLI 0.001
Multivariate analysis P HR
Persistent MRD-positive state post-DLI <0.0001 21.04
No chronic GvHD post-DLI 0.035 3.56
HSCT hematopoietic stem cell transplantation, HLA human leucocyte antigen,
GvHD graft-vs.-host disease, DLI donor lymphocyte infusion, BM bone marrow,
MNC mononuclear cell, MRD minimal residual disease
aThe cytogenetic subgroups are according to the published data [35, 36]
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recovery with a median time of 17 day, 45 trial subjects
achieved platelet recovery with a median time of
20 days, and only 3 subjects died of infection. All the
results confirmed the safety of chemotherapy and DLI
which used G-CSF mobilized peripheral blood cells
followed by CSA or MTX to prevent GvHD. As well,
due to the improvement of diagnosis and treatment of
GvHD and infectious disease post-transplant, it also
ensured the successful use of multiple consolidation
chemotherapy and DLIs. Moreover, because multiple
consolidation chemotherapy and DLIs were given
based on the results of MRD test and GvHD post-DLI,
therefore, it avoided unnecessary TRM while could
prevent second relapse in patients with relapsed acute
leukemia post-transplant.
Besides, although multiple consolidation chemother-
apy and DLIs were given, nine patients were still in a
positive MRD test and seven out of nine patients
relapsed again post-DLI. Mo et al. [9] also found that
early-onset positive MRD test after DLI and persistent
positive MRD test after DLI were usually associated with
increased relapse risk (P = 0.001) and impaired LFS (P =
0.004). Therefore, for those patients with a positive
MRD test post-DLI, more intensive therapy should be
used so as to make them maintain a persistent negative
MRD test. Mo et al. [28] found that in patients who
were in a positive MRD test post-transplant, compared
with DLI, interferon-α (IFN-α) could provide compar-
able rate of negative MRD test, relapse rate (27.3 % vs.
35.6 %, P = 0.514) and disease-free survival (68.2 vs.
60.0 %, P = 0.517). Furthermore, even in patients who
had unsatisfied response to DLI, IFN-α could also pro-
vide a decreased level of MRD or a negative MRD test
[29]. Besides, some articles have already suggested that
second transplant could offered a chance of stable re-
mission for patients with acute leukemia relapsing
post-transplant and provided a 25–30 % of survival
[30, 31]. Moreover, our previous study found that in 24
patients receiving second transplant to treat relapsed
acute leukemia post-transplant, although 12 patients
had no response to chemotherapy and DLI, second
transplant still provided 55.7 % of CIR, 35.1 % of non-
relapse mortality and 30.9 % of survival [32]. There-
fore, for patients who had a persistent positive MRD
test after two courses of consolidation chemotherapy
and DLIs, DLI followed by IFN-α or second transplant
were probably alternative methods. This needed to be
investigated in future.
In addition, in this study, the complete remission rate
(67 %, 47/60) is higher than that in article published
before [3]. This is maybe due to the application of
chemotherapy before DLI. Collins RH et al. [33] reported
that complete remission rate in AML (n = 39) and ALL
(n = 11) patients who had not received chemotherapy
before DLI were only 15.4 and 18.2 %, respectively. But,
in the article from Schmid C et al. [3], 75 % AML patients
received chemotherapy before DLI and 35 % patients
achieved complete remission. Besides, our previous study
also suggested that chemotherapy and DLI provided a
64 % of complete remission rate in subjects with relapsed
acute leukemia post-transplant [4]. Another reason is
maybe due to the infusion of G-CSF mobilized peripherial
blood cells infusion instead of unstimulate donor lym-
phocytes. Morris et al. [25] confirmed that using G-CSF
during blood cell mobilization augments NK-T-cell-
dependent CD8+ cytotoxicity. As well, our previous
study suggested that compared with chemotherapy and
DLI with unstimulated lymphocytes, chemotherapy and
G-CSF mobilized peripherial blood cells infusion tended
to be associated with a higher complete remission rate
(7/9 vs. 3/5) in patients with relapsed acute leukemia
after allo-HSCT [26]. In addition, Levine JE et al. [34]
also reported that chemotherapy and DLI with G-CSF
mobilized peripherial blood cells infusion could make
27 patients (27/57, 47 %) achieve complete remission.
Of course, there are some limitations to interpreting
data from our study. The most important one is that
historical cases were used as control, rather than ran-
domized control. But, most variable were comparable
between study group and historical control except for
donor types (P = 0.037). In study group, more subjects
receive a HLA-haplotype-matched transplant compared
with historical control (66 % vs. 56 %, P = 0.037). How-
ever, the impact of this imbalance should be to increase
rather than decrease the difficulties in interventions. As
well, because multiple consolidation chemotherapy and
DLIs were given based on the results of MRD tests and
GvHD, therefore, it is difficult to perform randomized
control study.
Conclusion
These data confirmed that after induction chemotherapy
and DLI, MRD test results and GvHD-guided multiple
consolidation chemotherapy and DLIs reduced CIR and
improved LFS and survival in patients with relapsed
acute leukemia post-transplant.
Acknowledgements
This manuscript has been revised by Prof. Robert peter Gale.
Funding
This study was supported by National Natural Science Foundation of China
(Grant No. 81400142), The Key Program of National Natural Science Foundation
of China (Grant No. 81230013), and Health Science Promotion Project of Beijing
(project TG-2015-003).
Availability of data and materials
Not applicable.
Yan et al. Journal of Hematology & Oncology  (2016) 9:87 Page 9 of 11
Authors’ contributions
X-jH designed the research. C-hY analyzed the data and prepared the typescript.
The other authors provided the subject data. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Peking University
People’s Hospital and written informed consent was obtained from all
subjects in accordance with the Declaration of Helsinki.
Received: 1 August 2016 Accepted: 6 September 2016
References
1. Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, Bacigalupo A,
Arcese W, Koc Y, Beelen D, Gülbas Z, Wu D, Santarone S, Tischer J, Afanasyev B,
Schmid C, Giebel S, Mohty M, Nagler A. Impact of conditioning intensity
in T-replete haplo-identical stem cell transplantation for acute leukemia:
a report from the acute leukemia working party of the EBMT. J Hematol
Oncol. 2016;9:25–37.
2. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J,
Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan
reduces conditioning regimen related toxicity following allogeneic
hematopoietic cell transplantation for acute myelogenous leukemia.
J Hematol Oncol. 2010;3:36–45.
3. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L,
Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC,
Kolb HJ, Rocha V, EBMT Acute Leukemia Working Party. Donor lymphocyte
infusion in the treatment of first hematological relapse after allogeneic stem-
cell transplantation in adults with acute myeloid leukemia: a retrospective risk
factors analysis and comparison with other strategies by the EBMT Acute
Leukemia Working Party. J Clin Oncol. 2007;25(31):4938–45.
4. Yan CH, Wang JZ, Liu DH, Xu LP, Chen H, Liu KY, Huang XJ. Chemotherapy
followed by modified donor lymphocyte infusion as a treatment for
relapsed acute leukemia after haploidentical hematopoietic stem cell
transplantation without in vitro T-cell depletion: superior outcomes
compared with chemotherapy alone and an analysis of prognostic
factors. Eur J Haematol. 2013;91(4):304–14.
5. Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ. Monitoring MRD
with flow cytometry: an effective method to predict relapse for ALL patients
after allogeneic hematopoietic stem cell transplantation. Ann Hematol.
2012;91(2):183–92.
6. Zhao XS, Jin S, Zhu HH, Xu LP, Liu DH, Chen H, Liu KY, Huang XJ. Wilms’
tumor gene 1 expression: an independent acute leukemia prognostic
indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant.
2012;47(4):499–507.
7. Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY, Qin YZ, Wang Y, Huang XJ.
Combined use of WT1 and flow cytometry monitoring can promote
sensitivity of predicting relapse after allogeneic HSCT without affecting
specificity. Ann Hematol. 2013;92(8):1111–9.
8. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ,
Huang XJ. Risk stratification-directed donor lymphocyte infusion could
reduce relapse of standard-risk acute leukemia patients after allogeneic
hematopoietic stem cell transplantation. Blood. 2012;119(14):3256–62.
9. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W,
Wang FR, Wang JZ, Liu KY, Huang XJ. Salvage chemotherapy followed by
granulocyte colony-stimulating factor-primed donor leukocyte infusion
with graft-vs.-host disease control for minimal residual disease in acute
leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem
cell transplantation: prognostic factors and clinical outcomes. Eur J
Haematol. 2016;96(3):297–308.
10. Yan C, Xu L, Liu D, Chen H, Wang Y, Liu K, Huang X. Immunosuppression
for 6-8 weeks after modified donor lymphocyte infusion reduced acute
graft-versus-host disease without influencing graft-versus-leukemia effect
in haploidentical transplant. Chin Med J (Engl). 2014;127(20):3602–9.
11. Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX.
Administration of short-term immunosuppressive agents after DLI reduces
the incidence of DLI associated acute GVHD without influencing the GVL
effect. Bone Marrow Transplant. 2009;44(5):309–16.
12. Wang YZ, Liu YR, Zhu HH, Wu HH, Cao H, Chan Y, Hao L, Jiang B, Huang XJ.
Prognostic significance of minimal residual disease detected by multiparameter
flow cytometry in acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za
Zhi. 2009;17(3):551–6.
13. Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W, Chen H, Wang FR,
Mo XD, Zhang YY, Huo MR, Zhao XS, Y K, Liu KY, Huang XJ. Donor-specific
anti-human leukocyte antigen antibodies were associated with primary
graft failure after unmanipulated haploidentical blood and marrow
transplantation: a prospective study with randomly assigned training
and validation sets. J Hematol Oncol. 2015;8:84–94.
14. Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P,
Li QC, Zhang ZM, Liu KY, Huang XJ. Multicenter phase ii study of a combination
of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD
prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative
Group (CBMTCG). J Hematol Oncol. 2014;7(1):59–71.
15. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY,
Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY. Conditioning including
antithymocyte globulin followed by unmanipulated HLA-mismatched/
haploidentical blood and marrow transplantation can achieve comparable
outcomes with HLA-identical sibling transplantation. Blood. 2006;
107(8):3065–73.
16. Tomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG,
Glucksberg H, Buckner CD. Bone marrow transplantation. N Engl J Med.
1975;292(17):895–902.
17. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P,
Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R,
Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD,
Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G,
Flowers ME. National Institutes of Health consensus development project
on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis
and staging working group report. Biol Blood Marrow Transplant. 2005;
11(12):945–56.
18. Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ. Minimal residual
disease as a predictive factor for relapse after allogeneic hematopoietic
stem cell transplant in adult patients with acute myeloid leukemia in first
and second complete remission. Cancers (Basel). 2012;4(2):601–17.
19. Wertheim GB, Bagg A. Minimal residual disease testing to predict relapse
following transplant for AML and high-grade myelodysplastic syndromes.
Expert Rev Mol Diagn. 2011;11(4):361–6.
20. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF,
Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V,
Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Prognostic
factors for donor lymphocyte infusions following non-myeloablative
allogeneic stem cell transplantation in multiple myeloma. Bone Marrow
Transplant. 2006;37(12):1135–41.
21. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D,
Bregante S, di Grazia C, Dominietto A, Soracco M, Romagnani C, Vassallo F,
Casini M, Bruno B, Frassoni F, Bacigalupo A. Factor predicting response and
graft-versus-host disease after donor lymphocyte infusion: a study on 593
infusions. Bone Marrow Transplant. 2003;31(8):687–93.
22. Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y, Chen H, Chen YH,
Han W, Huang XJ. Modified donor lymphocyte infusion-associated
acute graft-versus-host disease after haploidentical T-cell-replete
hematopoietic stem cell transplantation: incidence and risk factors.
Clin Transplant. 2012;26(6):868–76.
23. Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness
and alteration of immunological cells of bone marrow grafts using granulocyte
colony-stimulating factor. Haematologica. 2004;89(12):1517–24.
24. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and
polarization potential of T cells after in vitro mixture of G-CSF mobilized
peripheral blood grafts and G-CSF primed bone marrow grafts in different
proportions. Transpl Immunol. 2007;17(3):193–7.
25. Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger
HM, Burman AC, Olver SD, Kienzle N, Porcelli SA, Pellicci DG, Godfrey DI,
Smyth MJ, Hill GR. NKT cell-dependent leukemia eradication following
stem cell mobilization with potent G-CSF analogs. J Clin Invest. 2005;
115(11):3093–103.
Yan et al. Journal of Hematology & Oncology  (2016) 9:87 Page 10 of 11
26. Huang XJ, Guo NL, Ren HY, Zhang YC, Gao ZY, Xu LP, Lu DP. The comparison
of GVL effects between the patients receiving donor peripheral blood stem
cells and donor lymphocytes after allogeneic bone marrow transplantation.
J Peking Univ (health science). 2003;35(1):103–7.
27. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli
G, Bonfichi M, Pagnucco G, Salvaneschi L, Bernasconi C. Chemotherapy and
donor peripheral blood progenitor cells for acute leukemia in early relapse
after allogeneic bone marrow transplantation. Bone Marrow Transplant.
1999;23(6):607–12.
28. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR,
Wang JZ, Liu KY, Huang XJ. Interferon-α: a potentially effective treatment
for minimal residual disease in acute leukemia/myelodysplastic syndrome
after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. 2015;21(11):1939–47.
29. Mo XD, Zhao XY, Xu LP, Liu DH, Zhang XH, Chen H, Wang Y, Huang X.
Interferon α: the salvage therapy for patients with unsatisfactory response
to minimal residual disease-directed modified donor lymphocyte infusion.
Chin Med J (Engl). 2014;127(14):2583–7.
30. Chueh HW, Lee SH, Sung KW, Yoo KH, Koo HH. Second allogeneic stem cell
transplantation in hematologic malignancies: a single-center experience.
J Pediatr Hematol Oncol. 2013;35(6):424–9.
31. Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhauser M,
Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ,
Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N,
Bertz H, Schrezenmeier H, Schmid C. Second allograft for hematologic
relapse of acute leukemia after first allogeneic stem-cell transplantation
from related and unrelated donors: the role of donor change. J Clin
Oncol. 2013;31(26):3259–71.
32. Chen YH, Xu LP, Chen H, Liu DH, Zhang XH, Han W, Wang FR, Wang JZ,
Wang Y, Zhao T, Chen Y, Zhang YY, Yan CH, Sun YQ, Liu KY, Huang XJ.
The efficacy and safety of second allogeneic hematopoietic stem cell
transplantation for post-transplant hematologic malignancies relapse.
Zhonghua Nei Ke Za Zhi. 2011;50(6):489–91.
33. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R,
Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N,
Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients
with relapsed malignancy after allogeneic bone marrow transplantation.
J Clin Oncol. 1997;15(2):433–44.
34. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR,
Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M,
Collins Jr RH. Prospective trial of chemotherapy and donor leukocyte
infusions for relapse of advanced myeloid malignancies after allogeneic
stem-cell transplantation. J Clin Oncol. 2002;20(2):405–12.
35. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A,
Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR.
Karyotypic analysis predicts outcome of preremission and postremission
therapy in adult acute myeloid leukemia: a Southwest Oncology Group/
Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83.
36. Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM,
Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L,
Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH,
Dewald GW, Adult Leukaemia Working Party, Medical Research Council/
National Cancer Research Institute. Karyotype is an independent prognostic
factor in acute lymphoblastic leukaemia: analysis of cytogenetic data
from patients treated on the MRC UKALL XII/ECOG 2993 trial. Blood.
2007;109(8):3189–97.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yan et al. Journal of Hematology & Oncology  (2016) 9:87 Page 11 of 11
